Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2020-01-30 Earnings Release
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 98% confidence The document explicitly states it publishes 'Information financière du 4 ème trimestre 2019' (Financial information for the 4th quarter of 2019) and provides detailed, non-audited revenue figures and cash flow data for the period ending December 31, 2019. It also includes a forward-looking calendar mentioning the 'Résultats annuels 2019' (Annual results 2019) release date. This content structure—focusing on quarterly financial performance highlights and key figures—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) as it explicitly states the data is 'non auditées' (unaudited) and focuses on period results rather than the full annual filing. Q4 2019
2020-01-30 French
Inside Information / News release on accounts, results
Earnings Release Classification · 99% confidence The document explicitly announces 'Financial Information for the Fourth Quarter of 2019' and provides detailed, unaudited revenue figures for Q4 2019 and the full year 2019, comparing them to 2018. It also includes a financial structure update as of December 31, 2019, and an indicative schedule for future results releases. This content structure—focusing on recent period financial performance highlights without being a full annual report (10-K) or a formal comprehensive interim report (IR)—is characteristic of an Earnings Release (ER). The document is a press release format, not a comprehensive statutory filing. Q4 2019
2020-01-30 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 95% confidence The document is a 'Bilan semestriel du Contrat de Liquidité' (Semi-annual statement of the Liquidity Contract) for Genomic Vision, detailing share transactions (purchases and sales) executed under a liquidity agreement with CM-CIC Securities for the second half of 2019, and comparing it to the first half of 2019. This type of filing reports on the execution of a specific financial arrangement (liquidity contract/market making) and provides periodic updates on share movements related to that contract. It is not a comprehensive annual report (10-K), an earnings release (ER), or a standard interim financial report (IR). It is a specific regulatory disclosure related to market operations and share activity. Given the options, this specialized report on share transactions related to a liquidity agreement fits best under 'Transaction in Own Shares' (POS) if it were about buybacks, but since it's about a liquidity contract, it's a specific type of share transaction reporting. However, none of the codes perfectly match 'Liquidity Contract Statement'. Since it details transactions in the company's own shares (even if managed by a third party for liquidity purposes), POS is the closest fit among the specific codes related to share movement. If it were a general regulatory announcement without specific content matching other codes, RNS would be the fallback. Given the detailed transactional data, POS is more specific than RNS. The document is comprehensive (24k chars) and contains the data itself, not just an announcement of the data, so RPA is ruled out. POS covers 'Report of the company buying back or selling its own shares (share repurchase/issuance)'. While this is a liquidity contract, the underlying activity is managing the stock float, making POS the most appropriate specific classification.
2020-01-23 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is an 'Information relative au nombre total de droits de vote et d'actions composant le capital social' (Information relative to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and voting rights as of a specific date (31.12.2019). This content directly relates to the structure of the company's capital and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it is a specific declaration about the total number of shares and voting rights, which is a fundamental aspect of capital structure reporting, SHA is the most precise fit among the provided options, as it deals with the composition of the capital.
2020-01-21 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Genomic Vision's technology will be tested by NIST for establishing standards related to Genome Editing products, which is a significant operational and strategic development. It contains quotes from company management and NIST representatives, details about a consortium, and forward-looking statements. This type of announcement, detailing business progress, partnerships, or technological validation, is typically classified as a general corporate announcement or news release. Since it is not a formal regulatory filing like a 10-K, a specific financial report (ER, IR), a management discussion (MDA), or a proxy statement (DEF 14A), the most appropriate category is the general Regulatory Filings (RNS) category, which serves as a fallback for significant, non-standard corporate news releases that are often filed with regulators.
2020-01-21 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Genomic Vision announcing that its molecular combing technology will be tested by the NIST (National Institute of Standards and Technology) to establish standard methods for FDA registration of genome editing products. It details participation in a NIST consortium, quotes company and NIST personnel, and includes standard boilerplate information about the company and forward-looking statements. This type of announcement, which communicates a significant business development, partnership, or regulatory milestone outside of routine financial reporting (like earnings or annual reports), is best classified as a general Regulatory Filing or announcement. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific corporate action announcement (DIV, CAP, DIRS), and it is a formal communication to the market, it fits best under the general regulatory announcement category, RNS, as it is a significant, non-financial regulatory/standards-related update.
2020-01-21 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.